AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
A late-stage clinical trial failed to miss its primary endpoint, U. K. 's laregst drugmaker said Thursday.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC